A rare policy consensus emerges as AI’s impact moves beyond innovation into governance and societal risk
Updated
May 5, 2026 5:42 PM
A mechanical hand reaching for the hand of flesh. PHOTO: UNSPLASH
A new survey from Povaddo, a policy research firm, suggests that concern about artificial intelligence is no longer limited to industry or academia. It is now firmly present within the policy community.
The survey draws on responses from 301 public policy professionals across the United States and Europe, including lawmakers, staffers and analysts involved in shaping and evaluating public policy. A majority of respondents—61%—say governments are falling short in addressing the negative impacts of AI.
There is also broad agreement that regulation needs to increase. In the United States, 92% of respondents support stronger AI regulation, compared to 70% in Europe. At a time when consensus is often difficult, the findings point to a shared view across policy circles that current frameworks are not keeping pace with technological development.
Differences emerge when looking at how AI is affecting national contexts. In the U.S., 57% of policy experts believe AI is already harming the labor market. In Europe, 34% say the same. U.S. respondents are also more likely to see AI as a greater threat to jobs than immigration, with 63% holding that view compared to 47% in Europe.
On misinformation, responses are closely aligned. A large majority of policy experts in both regions expect an AI-driven misinformation crisis within the next one to two years—87% in the U.S. and 82% in Europe. Many also believe that AI-generated or AI-amplified misinformation could affect elections and public health information.
Some respondents frame the risks in more fundamental terms. In the United States, 41% of policy experts say AI poses an existential threat to humanity. In Europe, 29% share that view. U.S. respondents are also more likely to believe that advances in AI could harm global security and stability.
The findings come as policymakers begin to respond more actively. In the U.S., Senators Josh Hawley, Richard Blumenthal and Mark Warner have introduced bipartisan legislation focused on AI accountability, including measures aimed at protecting workers and children.
In Europe, the introduction of the EU AI Act marks a more advanced regulatory approach. The framework sets out rules based on levels of risk and is widely seen as the first comprehensive attempt to govern AI at scale.
William Stewart, President and Founder of Povaddo, said: "What makes these findings so significant is who is saying it. These are the practitioners who work inside the policy process every day, spanning every corner of the policy world from defense to healthcare to finance, not activists or everyday citizens. These findings foreshadow real action. The current path of governments accelerating AI deployment while falling short on governance is not sustainable, and the people who know that best are the ones in this survey. You cannot have nine-in-ten policy insiders demanding more regulation and four-in-ten calling AI an existential threat without that eventually moving the needle in Washington and Brussels in terms of legislative or regulatory action".
Taken together, the survey reflects a shift in how AI is being discussed within policymaking circles. Concern is no longer limited to future risks. It is increasingly tied to current gaps in governance and the pace of deployment.
Keep Reading
A new bet on early heart failure detection and why women’s health is at the center.
Updated
January 8, 2026 6:28 PM
A doctor holding an artificial heart model. PHOTO: ADOBE STOCK
Heart disease does not always announce itself clearly, especially in women. Many of the symptoms are ordinary, including fatigue, shortness of breath and swelling. These signs are frequently dismissed or explained away. As a result, many women are diagnosed late, when treatment options are narrower and outcomes are worse. That diagnostic gap is the context behind a recent investment involving Ultromics and the American Heart Association’s Go Red for Women Venture Fund.
Ultromics is a health technology company that uses artificial intelligence to help doctors spot early signs of heart failure from routine heart scans. It has received a strategic investment from the American Heart Association’s Go Red for Women Venture Fund.
The focus of the investment is a long-standing blind spot in cardiac care. Heart failure with preserved ejection fraction, or HFpEF, affects millions of people worldwide, with women disproportionately impacted. It is one of the most common forms of heart failure, yet also one of the hardest to diagnose. Studies even show women are twice as likely as men to develop the condition and around 64% of cases go undiagnosed in routine clinical practice.
Ultromics works with a tool most patients already experience during heart care: the echocardiogram. There is no new scan and no added burden for patients. Its software analyzes standard heart ultrasound images and looks for subtle patterns that point to early heart failure. The goal is clarity. Give clinicians better signals earlier, before the disease advances.
“Heart failure with preserved ejection fraction is one of the most complex and overlooked diseases in cardiology. For too long, clinicians have been expected to diagnose it using tools that weren't built to detect it and as a result, many patients are identified too late,” said Ross Upton, PhD, CEO and Founder of Ultromics. “By augmenting physicians' decision making with EchoGo, we can help them recognize disease at an earlier stage and treat it more effectively.”
The stakes are high. Research suggests women are twice as likely as men to develop the condition and that a majority of cases are missed in routine clinical practice. That delay matters. New therapies can reduce hospitalizations and improve survival, but only if patients are diagnosed in time.
This is why early detection has become a priority for mission-driven investors. “Closing the diagnostic gap by recognizing disease before irreversible damage occurs is critical to improving health for women—and everyone,” said Tracy Warren, Senior Managing Director, Go Red for Women Venture Fund. “We are gratified to see technologies, such as this one, that are accepted by leading institutions as advances in the field of cardiovascular diagnostics. That's the kind of progress our fund was created to accelerate.”
Ultromics’ platform is already cleared by regulators for clinical use and is being deployed in hospitals across the US and UK. The company says its technology has analyzed hundreds of thousands of heart scans, helping clinicians reach clearer conclusions when traditional methods fall short.
Taken together, the investment reflects a broader shift in healthcare. Attention is shifting earlier—toward detection instead of reaction. Toward tools that fit into existing care rather than complicate it. In this case, the funding is not about introducing something new into the system. It is about seeing what has long been missed—and doing so in time.